Compare Neurocrine Biosciences Inc (NBIX) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Sirius XM Holdings Inc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Sirius XM Holdings Inc trades at $30.24 (market cap $10.30B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Sirius XM Holdings Inc pays a 3.53% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | SIRI | |
|---|---|---|
Market Cap | $17.40B | $10.30B |
Sector | Health | Media |
52-Week High | $180.55 | $31.22 |
52-Week Low | $123.10 | $19.92 |
Enterprise Value | $16.49B | $19.97B |
Dividend Yield | — | 3.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Sirius XM (SIRI) trades at $30.29, down 0.98% on the day, with a bullish technical signal from moving averages and recent earnings beats. The stock shows solid fundamentals with a P/E of 12.97, net income margin of 9.86%, and a recent dividend payment. Revenue stabilized around $8.6B in 2025 after a dip in 2024, while debt-to-asset ratio improved to 35.63%.
Outlook is positive with analyst consensus at Buy (58% of ratings) and a $30.71 price target, though risks include competitive pressures and reliance on subscription growth. The YouTube ad partnership and inclusion in the S&P MidCap 400 provide catalysts, but investors should monitor Q2 2026 earnings due July 30 for confirmation of trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
